Press release

Sema4 Launches New Genomic Testing and Digital Tools for Use in Oncology

Sponsored by Businesswire

Sema4, a patient-centered health intelligence company, today announced
the launch of several new genomic testing services and digital tools to
help oncologists deliver on the promise of precision medicine. Together,
these products provide a comprehensive approach that can be used
throughout a patient’s journey, from assessing risk to analyzing cancer
and monitoring in remission. Demonstrations of the products will be
available at Sema4’s booth (#7140) at the American Society for Clinical
Oncology 2019 Annual Meeting taking place in Chicago from May 31 to June

Sema4’s new genomic profiling solution that will soon be available for
oncology includes whole exome sequencing (for tumor and normal samples)
and whole transcriptome sequencing (for tumor samples only). Based on
250x tumor coverage and 100x normal coverage across all genes, with 100
million RNA reads, these services provide clinically actionable
information about a broad range of genomic variants, gene fusion and
alternative splicing, and tumor mutational burden and microsatellite
instability. The services are designed for use with FFPE, bone marrow,
blood, or saliva samples.

The new digital tools are built on Sema4’s innovative Centrellis™ health
intelligence platform and are currently used for research purposes. They

  • Patient Journey — providing an interactive timeline visualization of
    the patient’s health journey, complete with diagnoses, treatments,
    molecular profiles, and more
  • Cohort Builder — offering the ability to define groups of patients
    according to specific parameters such as stage, histology, and
    treatments to understand treatment patterns, identify appropriate
    clinical trials, and enable data-driven decisions about patient care
  • VONC — automated variant curation platform pulling from a wide array
    of databases to support curation of genetic information at scale with
    the most relevant clinical evidence to inform therapy decisions

Clinicians at the Mount Sinai Health System, together with Sema4, have
been jointly developing and piloting these digital tools for application
in oncology.

“Sema4 is helping the objectives of the Tisch Cancer Institute because
it’s aggregating clinical data sets on our patients. Marrying that with
the genomic information and deploying it in usable tools is allowing us
to have better insights about what’s happening in our patient
population,” said Ramon Parsons, MD, PhD, Director of the Tisch Cancer
Institute and Chair of the Department of Oncological Sciences at Icahn
School of Medicine at Mount Sinai.

William Oh, MD, Chief of the Division of Hematology and Medical Oncology
at Mount Sinai and Deputy Director of the Tisch Cancer Institute at the
Icahn School of Medicine at Mount Sinai commented: “Working with a large
healthcare system and as a practicing oncologist myself, the most
important thing is getting this molecular data and the informatics in a
timetable that allows me to continue to take care of my patients.
Working with a company like Sema4 allows us to make the best decisions
for our patients to get the best possible outcomes.”

According to Andrew Kaufman, MD, Vice Chairman of the Department of
General Thoracic Surgery at Mount Sinai, “In healthcare, like any other
industry, we’re really looking for efficiency in connecting the dots of
so much data. Sema4 has come up with a novel way to look at patient data
that is extremely powerful. I use these tools almost like a Google
search, looking up information about my patients’ clinical and
scientific data to give each person the best care.”

Elisa Port, MD, Chief of Breast Surgery and Director of the Dubin Breast
Center at Mount Sinai, commented: “Sema4 is going to have a very
widespread impact on the patients we treat here because the company’s
tests open up the opportunity for genetic testing across a much broader
base of patients and streamline and expedite the process. Sema4 helps us
by quickly getting us the genetic testing information we need so we can
make important clinical decisions about surgery options for each

“Sema4’s mission to help physicians implement precision medicine is
built on our deep foundation in data science and developing genomic
tests,” said Eric Schadt, PhD, Founder and Chief Executive Officer of
Sema4. “Our team’s expertise in data mining, analysis, machine learning,
and predictive modeling gives us a unique advantage in generating and
making sense of information in ways that will give oncologists an edge
in battling cancer, particularly when combined with advanced genomic

About Sema4

Sema4 is a patient-centered health intelligence company founded on the
idea that more information, deeper analysis, and increased engagement
will improve the diagnosis, treatment, and prevention of disease. Sema4
is dedicated to transforming healthcare by building dynamic models of
human health and defining optimal, individualized health trajectories,
starting in the areas of reproductive health and
oncology. Centrellis™, our innovative health intelligence platform, is
enabling us to generate a more complete understanding of disease and
wellness and to provide science-driven solutions to the most pressing
medical needs. Sema4 believes that patients should be treated as
partners, and that data should be shared for the benefit of all.

For more information, please visit
and connect with Sema4 on Twitter,
Facebook and YouTube.